155.96MMarket Cap-1.21P/E (TTM)
2.280High2.115Low675.67KVolume2.130Open2.120Pre Close1.51MTurnover1.69%Turnover RatioLossP/E (Static)70.57MShares16.24052wk High0.36P/B88.43MFloat Cap1.96052wk Low--Dividend TTM40.01MShs Float79.160Historical High--Div YieldTTM7.78%Amplitude1.280Historical Low2.229Avg Price1Lot Size
Nkarta Stock Forum
$Nkarta (NKTX.US)$
nfa
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
Nkarta | SC 13G: Statement of acquisition of beneficial ownership by individuals-Kenneth Griffin(5.4%),Citadel Advisors LLC(4.5%), etc.
morning star? bottom now with big vol. buy now?
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in my...
Nkarta Announces Ind Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
boom boom boom boom 💥 getting richer from my room 🤣
$Nkarta (NKTX.US)$
$Nkarta (NKTX.US)$
I don't know why I didn't share it in my previous post or why I just thought to share it now 🤷🏽 but here we go. this is what I shared with the group.
I know i said not to buy ibrx because it was too volatile. I've changed my tune because of my biopharma outlook.... want it's twin?
cancer killing cell developer, starting with leukemia! buy rating at 17 (i think it pops to 23, but 19 is the full extension) 👌
see that daily turnaround? that's a bottom
see the accumulation at th...
I shared this with my group. I like cancer treatment biostocks 😁
$Nkarta (NKTX.US)$
No comment yet